Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623
This examiner grants 56% of resolved cases
Sophia P. Hirakis is an examiner in Tech Center 1600 and Art Unit 1623, with 57 resolved cases. Her allowance rate is 56.1%, and the median days to allowance is 1363. These metrics suggest a moderate probability of success but a relatively long timeline to reach a grant. With 57 resolved cases, the data provides an emerging profile of her examination style in this art unit.
The interview lift pct of 73.5% is exceptionally high, indicating that interviews are an incredibly powerful tool for this examiner. This lift suggests that an interview can dramatically improve the 56.1% allowance rate, making it one of the most effective strategies available to practitioners. Given the 1363 median days to allowance, an interview is not just helpful for success but likely essential for navigating a long prosecution efficiently. The 57 resolved cases highlight the significant impact that direct communication can have on her decisions.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17643623 | QUINAZOLINYL COMPOUNDS AND METHODS OF USE | Non-Final OA | Genentech, Inc. |
| 18557258 | Use of Terpenoids and Salicylates as Anesthetics and Analgesics | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18026330 | LIGHT-CONTROLLED BIOORTHOGONAL TETRAZINE LIGATION | Non-Final OA | The Regents of the University Of California |
| 18032067 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | Final Rejection | Bayer Aktiengesellschaft |
| 18085182 | FUNGICIDAL COMBINATIONS | Final Rejection | UPL Europe LTD |
| 18559689 | Substituted Spiro Derivatives | Non-Final OA | Janssen Pharmaceutica NV |
| 18272845 | COMPOUNDS AND METHODS FOR TREATING MALARIA | Non-Final OA | The United States Of America As Represented By The Secretary, Department of Health and Human Service |
| 18155587 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | Final Rejection | MUSC Foundation for Research Development |
| 18043441 | COMPOUNDS AND METHODS FOR INHIBITION OF BAX-MEDIATED CELL DEATH | Final Rejection | Albert Einstein College of Medicine |
| 17641257 | COMBINATION OF ZIDOVUDINE AND FLUOROQUINOLONE ANTIBIOTIC | Final Rejection | HELPERBY THERAPEUTICS LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy